Good for Business, Lithuania, Markets and Companies, Medicine
International Internet Magazine. Baltic States news & analytics
Wednesday, 21.05.2025, 05:47
Sicor Biotech ups profit to EUR 74 mln in 2016
BC, Vilnius, 24.07.2017.
Print version
Print versionLithuania's leading biopharmaceutical manufacturer Sicor Biotech, which is controlled by the international generic drugs producer Teva, posted a net profit of 74.014 million euros for 2016, up by 8.8%, from 68 million euros, in 2015, reports LETA/BNS.
 |
|---|
Annual revenue rose by 15.2% to 195.216 million euros, the company said in
its 2016 annual report filed with the Center of Registers.
Sicor Biotech revenue in the US grew by 4.2% to 131.7 million euros, while the revenue
in the Baltic states soared 55.8% to 38.2 million euros. Another 4.9 million
euros in revenue was received in Turkey and France each. The company's revenue
from drugs production and sales was virtually unchanged over the year at 132.6
million euros, while wholesale in products of Teva and other manufacturers were
up 74.2% to 62.5 million euros.
Dutch-registered Gatio Investments,
which is part of Israel's Teva
Pharmaceutical Industries Group, owns 100% of shares in Sicor Biotech.
«The Baltic Course» Is Sold and Stays in Business!
